151751-Najiba-Chargi

241 Systemic therapy: skeletal muscle mass and anti-cancer drug toxicity Table 1. Characteristics of included studies Author and Date n Type of Cancer Measure low SMM Occurrence low SMM n (%) or Mean (SD) Location Analyzed Anti-Cancer Drug Measure of Toxicity Occurrence Toxicity n (%) Anandavadivelan et al. 2016 41 72 Oesophageal 1 31 (43.0%) CT-L3 Cisplatin + 5-FU DLT a Not given Antoun et al. 2010 42 55 Renal cell 1 30 (54.5%) CT-L3 Sorafenib DLT a 12 (21.8%) Barret et al. 2014 5 51 Metastatic colorectal 1 36 (70.6%) CT-L3 FP with/without oxaliplatin or irinotecan with/without cetuximab ≥grade 3 toxicity 14 (27.5%) Chemama et al. 2016 43 97 Peritoneal carcinomatosis and colorectal 2 39 (40.0%) CT-L3 HIPEC oxaliplatin + irinotecan ≥grade 3 toxicity 33 (39.0%) Cushen et al. 2016 44 63 Metastatic castrate resistant prostate 2 30 (47.6%) CT-L3 Docetaxel-based DLT a 22 (34.9%) Cushen et al. 2017 45 55 Clear cell renal cell 3 13 (23.6%) CT-L3 Sunitinib DLT a 40 (73.0%) Daly et al. 2017 21 84 Metastatic melanoma 2 20 (23.8%) CT-L3 Ipilimumab ≥grade 3 toxicity 35 (41.7%) Da Rocha et al. 2019 20 60 Gastro-intestinal 2 14 (23.3%) CT-L3 5-FU+ leucovorin, FOLFOX, or paclitaxel + carboplatin DLT a during first cycle 14 (23.3%) Dijksterhuis et al. 2019 22 88 Esophago-gastric 2 43 (48.9%) CT-L3 CAPOX ≥grade 3 toxicity during first cycle 32 (36.4%) Freckelton et al. 2019 23 52 Metastatic pancreatic ductal adenocarcinoma 1 30 (57.7%) CT-L3 Gemcitabine + nab-paclitaxel ≥grade 3 toxicity during first cycle 14 (27.0%) Ganju et al. 2019 24 246 Head and neck 2 143 (58.0%) CT-C3 Cisplatin, cetuximab, or carboplatin DLT a 91 (37.0%) Huillard et al. 2013 7 61 Metastatic renal cell 1 32 (52.5%) CT-L3 Sunitinib DLT a during first cycle 18 (29.5%) Huiskamp et al. 2020 25 91 Head and neck ≤45.2 cm 2 /m 2 68 (74.7%) CT-C3 MRI-C3 Cetuximab DLT a 28 (30.8%) Kobayashi et al. 2019 26 23 Inoperable soft tissue sarcoma <39 cm 2 /m 2 11 (47.8%) CT-L3 Eribulin ≥grade 3 toxicity 16 (69.6%) Kurk et al. 2019 27 414 Metastatic colorectal 2 198 (47.8%) CT-L3 CAPOX-B or CAP-B DLT a 130 (56.0%) 111 (61.0%) b Looijaard et al. 2019 28 53 Colorectal Continuous SMI 46.3 (8.9) CT-L3 Capecitabine, CAPOX, 5-FU+leucovorin, or FOLFOX DLT a 41 (77.4%) Mazzuca et al. 2018 29 21 Stage 1–3 breastcancer ≤38.5 cm 2 /m 2 8 (38.1%) CT-L3 A combination of 2–3: adriamycin, paclitaxel, docetaxel, epirubicin, trastuzumab, 5-FU, or cyclophosphamide ≥grade 3 toxicity Not given 13